-
Mashup Score: 7IMAGE study: Isatuximab plus pomalidomide and dexamethasone for RRMM in the real-world setting - 3 hour(s) ago
Here we present a visual abstract of a retrospective study by Decaux et al. which evaluated real-world outcomes following at least one dose of Isa-Pd for the treatment of RRMM.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Symposium | Panel discussion | Strategies for the management of treatment-related toxicities in MM - 27 day(s) ago
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies in early RRMM. Mohamad Mohty chaired a second panel discussion, joined by expert speakers Martin Kaiser and Rakesh Popat, focusing on strategies for the management of treatment-related toxicities in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
🎥 Watch our latest panel discussion, recorded during #ESHMM2024, chaired by Mohamad Mohty and featuring experts Martin Kaiser and @DrRakeshPopat, on how to manage treatment-related toxicities in MM. Catch up here 👉 https://t.co/tTWL6PZlxK #mmsm #myeloma @Mohty_EBMT @MyMKaiser https://t.co/iA1S4jLFNx
-
-
Mashup Score: 0IWWM-12: What are the implications of iStopMM for MM and WM? - 28 day(s) ago
During IWWM-12, the Lymphoma Hub was pleased to speak to Sæmundur Rögnvaldsson, University of Iceland, Reykjavik, IS. We asked about the iStopMM study and the implications of these data for both patients with multiple myeloma and those with Waldenstrom’s macroglobulinemia.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
#IWWM12 | The Multiple Myeloma Hub was pleased to speak to @SaemundurMD. We asked about the iStopMM study and the implications of these data for both patients with #MultipleMyeloma and those with #WaldenstromMacroglobulinemia: https://t.co/dQjpDHQGVx @uni_iceland #mmsm #myeloma https://t.co/4gCTzYXrgm
-
-
Mashup Score: 33ASH 2024: Top abstracts in MM and other plasma cell dyscrasias - 29 day(s) ago
To help navigate the exciting content being presented at the ASH Congress 2024, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
🚨 #ASH24 is nearly here! The list of top abstracts selected by the #MultipleMyeloma Hub Steering Committee for the 66th ASH Annual Meeting and Exposition is now available to view 👉 https://t.co/k1viRSl2hx #MMsm https://t.co/SwCAQVKHsV
-
-
Mashup Score: 1Symposium | BCMA-directed ADCs for the treatment of MM - 29 day(s) ago
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence BCMA-directed therapies in early RRMM. During the symposium, Martin Kaiser delivered a presentation on BCMA-directed ADCs for the treatment of MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
🎥 How might BCMA-directed antibody–drug conjugates fit into the #MultipleMyeloma treatment paradigm? Check out our latest video with Martin Kaiser @MyMKaiser. Watch the full video here 👉 https://t.co/pvWAwq2bSw #mmsm #myeloma #ESHMM2024 https://t.co/GmVhBqhWFn
-
-
Mashup Score: 3Symposium | Panel discussion | Strategies for the management of treatment-related toxicities in MM - 1 month(s) ago
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies in early RRMM. Mohamad Mohty chaired a second panel discussion, joined by expert speakers Martin Kaiser and Rakesh Popat, focusing on strategies for the management of treatment-related toxicities in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
🎥 Watch our latest panel discussion, recorded during #ESHMM2024, chaired by Mohamad Mohty and featuring experts Martin Kaiser and @DrRakeshPopat, on how to manage treatment-related toxicities in MM. Catch up here 👉 https://t.co/tTWL6PZlxK #mmsm #myeloma @Mohty_EBMT @MyMKaiser https://t.co/iA1S4jLFNx
-
-
Mashup Score: 4
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies in early RRMM. Mohamad Mohty chaired a panel discussion, focusing on strategies for sequencing BCMA-directed therapies in RRMM, joined by expert speakers Martin Kaiser and Rakesh Popat.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
🎥 During #ESHMM2024, Mohamad Mohty chaired a panel discussion, featuring experts Martin Kaiser and Rakesh Popat, on how to sequence BCMA-directed therapies in R/R #MultipleMyeloma. Catch up here 👉 https://t.co/nw1HFbVVBT #mmsm #myeloma @Mohty_EBMT @MyMKaiser @DrRakeshPopat https://t.co/6fjYiFL5kH
-
-
Mashup Score: 10Symposium | Treatment paradigm in early RRMM - 1 month(s) ago
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies in early RRMM. During the symposium, Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK, delivered an expert presentation on the existing and developing treatment paradigm for early RRMM.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
The treatment paradigm for early relapsed/refractory #MultipleMyeloma is constantly evolving. Stay up to date by watching an expert presentation from @DrRakeshPopat @uclh on latest developments in early relapsed disease. 🎥 👉 https://t.co/k9gakrI7nI #mmsm #myeloma #ESHMM2024 https://t.co/af8ptReg8U
-
-
Mashup Score: 10Belantamab mafodotin combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma | GSK US - 1 month(s) ago
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
Source: us.gsk.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 @US_FDA accepts for review a BLA application for belantamab mafodotin, an investigational antibody-drug conjugate, in combination with Vd and with Pd for the treatment of RRMM with ≥1 prior LOT. Read more: https://t.co/kLdkC9et5i #MedNews #mmsm #myeloma… https://t.co/P0nVZs5LDi https://t.co/7pJFYyVM6O
-
-
Mashup Score: 9Symposium | Treatment paradigm in early RRMM - 1 month(s) ago
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium on: How to sequence BCMA-directed therapies in early RRMM. During the symposium, Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK, delivered an expert presentation on the existing and developing treatment paradigm for early RRMM.
Source: multiplemyelomahub.comCategories: General Medicine News, Oncologists1Tweet-
The treatment paradigm for early relapsed/refractory #MultipleMyeloma is constantly evolving. Stay up to date by watching an expert presentation from @DrRakeshPopat @uclh on latest developments in early relapsed disease. 🎥 👉 https://t.co/k9gakrI7nI #mmsm #myeloma #ESHMM2024 https://t.co/af8ptReg8U
-
How do real-world data for isatuximab-Pd in the treatment of relapsed/refractory #MultipleMyeloma align with clinical trial data? Read our latest article to learn more 👉 https://t.co/EZOFe5iL7E #mmsm #myeloma #RRMM https://t.co/SB9lcJrFbJ